Hogan Lovells has announced the return of Xin Tao to its Pharmaceutical and Biotechnology group, where he will advise life sciences, food, consumer platform, and technology companies on global compliance and cross-border transactions. Tao brings nearly 15 years of experience in the field, with a particular focus on clients headquartered in China or expanding their business across the Asia-Pacific region. As a former research scientist, he draws on that scientific background to provide practical advice on complex regulatory matters spanning pharmaceuticals, medical devices, food, cosmetics, and consumer technology — a combination of technical depth and legal expertise that is increasingly valuable in a period of heightened geopolitical and regulatory sensitivity.
Tao previously spent more than nine years at Hogan Lovells before departing, and his return comes as the firm works to deepen its capabilities in high-stakes compliance work with an emphasis on global market entry. His practice includes advising on US and EU regulatory systems alongside Asian business environments, helping clients navigate not just the legal dimensions of cross-border work but also the commercial and cultural ones. He has represented international companies in high-stakes US government investigations involving the Department of Justice, the FDA, the Federal Trade Commission, the Consumer Product Safety Commission, and proceedings before the US Congress on matters ranging from product safety and regulatory compliance to national security.
Tao’s arrival also comes in the context of a significant development for Hogan Lovells: the firm’s successful vote to become Hogan Lovells Cadwalader. Ajay Kuntamukkala, Office Managing Partner for Washington DC, noted that Tao will be a meaningful asset in deepening the firm’s regulatory offering in the capital for global companies seeking to do business in the United States, particularly given his familiarity with how Washington works. David Fox, Practice Area Leader for Pharmaceuticals and Biotechnology, added that Tao’s experience guiding Chinese companies through the unique regulatory challenges of global expansion complements the firm’s existing work.
Tao received his J.D. from Georgetown University Law Center, his M.S. in Biochemistry from Texas A&M University, and his B.S. in Biochemistry from Shanghai Jiaotong University. He says he has long valued Hogan Lovells’ fully integrated and well-balanced global platform, collaborative culture, and deep regulatory capabilities. The firm maintains exceptional strength across the world’s major economies, including a deep bench across the G20, and partners across jurisdictions who understand the needs of Chinese and other international clients navigating an increasingly uncertain regulatory environment.
KEY QUOTES:
“As the world operates in an environment characterized by heightened regulatory scrutiny and increasing geopolitical sensitivity, his arrival reinforces our commitment to expanding our high-stakes compliance work across the life sciences sector with an emphasis on global market entry, including from China.”
Janice Hogan, Practice Group Leader — Global Regulatory & IP, Hogan Lovells
“I am excited to return to Hogan Lovells and practice alongside this outstanding group of lawyers. Having previously spent more than nine years at the firm, I have long valued its fully integrated and well-balanced global platform, collaborative culture, and deep regulatory capabilities.”
Xin Tao, Partner, Hogan Lovells
